Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-02-23. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10.6% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: purposecomplease visitbmsstudyconnectvisit www
  Phrases that lowered it: participantsdrugsvisitclinicaltrial
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 92 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: 22.9% (raises risk) · Drug's FDA history
• Sponsor's past trials: 527 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 222765 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 86.7% (lowers risk) · Drug's FDA history
• Primary purpose: supportive care (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Collaborators: 1 (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Drugs with FDA adverse-event history: 6 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial NCT02057380 · started 2014 · scored riskier than 55% of active trials completed
• Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies NCT04164199 · started 2019 · scored riskier than 45% of active trials completed
• Open-label Extension Study of Brazikumab in Ulcerative Colitis NCT04277546 · started 2020 · scored riskier than 71% of active trials terminated
• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab NCT00930553 · started 2009 · scored riskier than 66% of active trials completed
• An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study NCT02488330 · started 2015 · scored riskier than 25% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.